TIDMDPH
RNS Number : 6478E
Dechra Pharmaceuticals PLC
19 October 2018
Date: 19 October 2018
Dechra(R) Pharmaceuticals PLC
Results of Annual General Meeting (AGM)
AGM Meeting Date: 10.30 am on 19 October 2018
Issued Share Capital at meeting date: 102,336,635
Number of shareholders in attendance: 9
All resolutions were passed on a show of hands.
Details of the proxy voting instructions lodged prior to the AGM
are set out below:
Resolution (No. as noted Total For (1) Total Against Withheld
on proxy form) (2)
No. of % of No. of % of No. of votes
votes vote votes vote
----------- ------- ---------- ------ -------------
Resolution 1:
To receive the accounts,
the Strategic Report,
the Directors' Report
and the Auditor's Report 73,623,740 95.88 3,162,913 4.12 377,261
----------- ------- ---------- ------ -------------
Resolution 2:
To approve the Directors'
Remuneration Report 76,045,670 98.58 1,092,914 1.42 25,330
----------- ------- ---------- ------ -------------
Resolution 3:
To declare a final dividend 77,160,743 100.00 3,172 0.00 0
----------- ------- ---------- ------ -------------
Resolution 4:
To re-elect William
Anthony Rice 71,931,907 93.24 5,212,000 6.76 20,007
----------- ------- ---------- ------ -------------
Resolution 5:
To re-elect Ian Page 76,265,790 98.84 898,039 1.16 86
----------- ------- ---------- ------ -------------
Resolution 6:
To re-elect Richard
Cotton 76,089,363 98.61 1,074,466 1.39 86
----------- ------- ---------- ------ -------------
Resolution 7:
To re-elect Anthony
Griffin 76,248,926 98.81 914,902 1.19 86
----------- ------- ---------- ------ -------------
Resolution 8:
To re-elect Julian Heslop 76,471,131 99.10 692,698 0.90 86
----------- ------- ---------- ------ -------------
Resolution 9:
To re-elect Ishbel Macpherson 76,540,810 99.22 603,098 0.78 20,007
----------- ------- ---------- ------ -------------
Resolution 10:
To re-elect Lawson Macartney 76,643,113 99.33 520,716 0.67 86
----------- ------- ---------- ------ -------------
Resolution 11:
To re-appoint PricewaterhouseCoopers
as external auditor
of the Company 76,021,787 98.52 1,141,654 1.48 473
----------- ------- ---------- ------ -------------
Resolution 12:
To authorise the Audit
Committee to determine
the remuneration of
the external auditor 76,655,223 99.34 508,169 0.66 523
----------- ------- ---------- ------ -------------
Resolution 13:
To authorise the Directors
to allot shares to specific
limits 75,498,018 97.84 1,664,325 2.16 1,572
----------- ------- ---------- ------ -------------
Resolution 14:
To disapply the pre-emption
rights 73,792,966 95.63 3,369,827 4.37 1,122
----------- ------- ---------- ------ -------------
Resolution 15:
To disapply additional
pre-emption rights 73,637,601 95.43 3,523,885 4.57 2,428
----------- ------- ---------- ------ -------------
Resolution 16:
To authorise the Company
to purchase its own
shares 76,382,960 99.00 773,210 1.00 7,744
----------- ------- ---------- ------ -------------
Resolution 17:
To call general meetings
(other than an AGM)
on not less than 14
clear days' notice 75,446,021 97.77 1,717,894 2.23 0
----------- ------- ---------- ------ -------------
Resolution 18:
(a) To approve the rules
of the Dechra Global
Save As You Earn Scheme
2018 (2018 SAYE Plan);
and
(b) To authorise the
Directors to adopt further
plans based on the 2018
SAYE Plan 76,738,556 99.45 423,701 0.55 1,658
----------- ------- ---------- ------ -------------
Notes
1. Includes discretionary votes.
2. A "vote withheld" is not a vote in law and is not counted in
the calculation of the proportion of votes "For" and "Against" a
resolution.
3. Resolutions 1 to 13 and Resolution 18 were ordinary
resolutions, requiring more than 50% of shareholder votes to be
"For" the resolutions.
4. Resolutions 14 to 17 were special resolutions, requiring more
than 75% of shareholder votes to be "For" the resolutions.
5. Votes tendered in respect of 77,163,915 shares representing
75.40% of the issued share capital.
In accordance with Listing Rule 9.6.2R, a copy of the
resolutions passed as special business at the AGM have been
submitted to the National Storage Mechanism and will shortly be
available for inspection at www.morningstar.co.uk/uk/nsm.
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. The majority of Dechra's
products are focused on key therapeutic categories where we have
leading market positions, and many of our products are used to
treat medical conditions for which there is no other effective
solution or have a clinical or dosing advantage over competitor
products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra
and the Dechra "D" logo are registered trademarks of Dechra
Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGEAAENFDSPFFF
(END) Dow Jones Newswires
October 19, 2018 08:37 ET (12:37 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024